Novavax, Inc. announced today the appointment of Timothy J.
Hahn, Ph.D., as Senior Vice President of Manufacturing. Dr. Hahn will oversee
production of the company's vaccines and vaccine candidates and be responsible
for all manufacturing operations at its pilot and commercial launch facility in
Rockville, MD. He will report to Novavax's President
and CEO Stanley Erck.
Mr. Erck stated: "Tim is a very talented manufacturing
executive who brings to Novavax extraordinary experience in vaccine
development, production and distribution. We look forward to applying his
unique expertise to our proprietary vaccine production methods as we and our
international partners work toward regulatory approval and launch of our
vaccine candidates to prevent the spread of influenza and other infectious
diseases worldwide."
Dr. Hahn commented: "I am honored to join Novavax and
lead its manufacturing team. Virus-like particles represent an important
innovation in the development and delivery of effective vaccines, and I look
forward to advancing this technology and Novavax's manufacturing network so
that we can deliver our vaccines wherever they are needed."
Prior to joining Novavax, Dr. Hahn was Vice President of
Antibody Manufacturing and later Vice President of Vaccine Manufacturing at
MedImmune, LLC. In these roles and as a member of the operations manufacturing
team, Dr. Hahn oversaw MedImmune's U.S. manufacturing sites in Frederick, MD
and Philadelphia, PA and non-U.S. sites in Nijmegen, The Netherlands and Speke,
UK with responsibility for bulk and fill production of commercial antibody and
vaccine products as well as fill manufacturing of clinical trial materials. Dr.
Hahn also coordinated the management of the integrated production processes for
the seasonal production of Synagis(R) and FluMist(R). As part of the leadership
team for the start-up of a new antibody manufacturing facility in Frederick,
MD, Dr. Hahn was responsible for the process validation and start-up strategy
and execution for the project, which was recognized as the 2011 ISPE Facility
of the Year Award Winner for Project Execution.
Previously, Dr. Hahn spent more than 15 years in vaccine
manufacturing with Merck & Co. He received his doctorate and Master of
Science degrees in chemical engineering from Stanford
University and his Bachelor of Science
degree in chemical engineering from Lehigh
University.